Non-invasive prenatal screening (NIPS) is currently offered in over 80 countries, covering over 80 million annual births, with an estimated volume of over one million screening tests performed annually. First offered in 2011, there has been rapid adoption of these genomic tests in the marketplace.
What lessons for liquid biopsy have been learned from fetal aneuploidy testing?
Posted by
Russell Garlick on Sep 30, 2016 1:06:00 PM
0 Comments Click here to read/write comments
Topics: NIPS, ctDNA, biomimetic technology, liquid biopsy, circulating DNA, cell-free, testing